Foghorn Therapeutics (FHTX) Non Operating Income (2019 - 2026)

Foghorn Therapeutics' Non Operating Income history runs 8 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• On a quarterly basis, Non Operating Income fell 58.37% year-over-year to $1.7 million in Q1 2026; TTM through Mar 2026 was $9.7 million, a 42.67% decrease from a year earlier, with the FY2025 full-year figure at $12.1 million, down 24.63% from the prior year.
• Non Operating Income retreated to $1.7 million in Q1 2026 per FHTX's latest filing, from $2.2 million in the prior quarter.
• Across five years, Non Operating Income topped out at $4.7 million in Q3 2024 and bottomed at $890000.0 in Q1 2022.
• The 5-year median for Non Operating Income is $3.2 million (2024), against an average of $3.0 million.
• Across the five-year window, Non Operating Income surged 1275.69% in 2022 and sank 58.37% in 2026, its largest moves.
• Year by year, Non Operating Income stood at $3.0 million in 2022, then advanced by 11.27% to $3.3 million in 2023, then jumped by 34.87% to $4.5 million in 2024, then plunged by 50.82% to $2.2 million in 2025, then decreased by 23.31% to $1.7 million in 2026.
• Per Business Quant, the three latest FHTX Non Operating Income figures stand at $1.7 million (Q1 2026), $2.2 million (Q4 2025), and $2.7 million (Q3 2025).